Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.600
-0.050 (-1.89%)
At close: May 1, 2026, 4:00 PM EDT
2.548
-0.052 (-1.99%)
After-hours: May 1, 2026, 5:26 PM EDT
Black Diamond Therapeutics Employees
Black Diamond Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 3 or -12.50% compared to the previous year.
Employees
21
Change (1Y)
-3
Growth (1Y)
-12.50%
Revenue / Employee
$3,333,333
Profits / Employee
$1,065,095
Market Cap
148.95M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 21 | -3 | -12.50% |
| Dec 31, 2024 | 24 | -30 | -55.56% |
| Dec 31, 2023 | 54 | -11 | -16.92% |
| Dec 31, 2022 | 65 | -21 | -24.42% |
| Dec 31, 2021 | 86 | 17 | 24.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| Fate Therapeutics | 161 |
| Molecular Partners AG | 134 |
| Alps Group | 93 |
| Agenus | 81 |
| Tenaya Therapeutics | 70 |
| Spero Therapeutics | 25 |
| Galectin Therapeutics | 9 |
BDTX News
- 10 days ago - Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 6 weeks ago - Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Black Diamond Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Black Diamond Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference - Transcripts
- 5 months ago - Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data - Benzinga
- 5 months ago - Black Diamond Therapeutics Transcript: Study Update - Transcripts
- 5 months ago - Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM - GlobeNewsWire